Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xeronacre+ is a topical dermocosmetic and therapeutic product developed by MEGA BIOPHARMA for the treatment and alleviation of psoriasis symptoms. The product is based on the company's proprietary NACR-45® technology, which utilizes the biomaterial nacre (mother-of-pearl). Nacre is known for its biocompatibility and potential to support tissue regeneration and skin health. Xeronacre+ is intended to manage psoriasis-related skin issues through the natural properties of nacre rather than through traditional pharmacological pathways or molecular targets. It is categorized as a medical device or dermocosmetic product rather than a traditional pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xeronacre+.